Author(s):
Yash Manoj Jadhav, Rupali Jalindar Ghule, Priyal Nilesh Jadhav, Samadhan Gajendra Jaybhave, Mukund M. Pache, Avinash B. Darekar
Email(s):
mukundpache918@gmail.com
DOI:
10.52711/2231-5691.2026.00039 
Address:
Yash Manoj Jadhav1, Rupali Jalindar Ghule1, Priyal Nilesh Jadhav1, Samadhan Gajendra Jaybhave1, Mukund M. Pache1, Avinash B. Darekar2
1Department of Pharmacology, K.V.N. Naik S.P. Sanstha's, Institute of Pharmaceutical Education and Research, Nashik, 422002, Maharashtra, India.
2Principal, K.V.N. Naik S.P. Sanstha's, Institute of Pharmaceutical Education and Research, Nashik, 422002, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
The transition from traditional drug delivery approaches to sophisticated, novel systems marks a transformative era in therapeutic science. Conventional methods often suffer from low bioavailability, systemic toxicity, and poor targeting, necessitating the development of more precise and effective solutions. Novel drug delivery systems (NDDS) have emerged as a cornerstone of modern pharmacology, leveraging advances in materials science, nanotechnology, and biomedical engineering. Innovative carrier platforms such as nanocarriers, lipid-based vesicles, and polymeric matrices have revolutionized how drugs are encapsulated, protected, and transported to disease sites. These materials enable smart drug delivery mechanisms that respond to physiological cues, such as pH or temperature, to ensure controlled and targeted release. Biological vectors like exosomes are also gaining traction for their innate biocompatibility and targeting capabilities. Together, these advances offer unprecedented control over pharmacokinetics and therapeutic index. The clinical impact of these systems spans a wide range of diseases. In oncology, targeted therapies using nanoparticles have significantly improved treatment specificity while minimizing collateral damage. For central nervous system (CNS) disorders, NDDS offer enhanced penetration of the blood-brain barrier. Infectious diseases also benefit from sustained and localized drug release, improving patient compliance and outcomes. Despite remarkable progress, challenges such as large-scale manufacturing, long-term safety, and regulatory hurdles remain. Future directions point toward more personalized, responsive, and multifunctional delivery systems, integrating diagnostics and therapeutics for a new era of precision medicine.
Cite this article:
Yash Manoj Jadhav, Rupali Jalindar Ghule, Priyal Nilesh Jadhav, Samadhan Gajendra Jaybhave, Mukund M. Pache, Avinash B. Darekar. Advances in Novel Drug Delivery Systems: Materials, Mechanisms and Therapeutic Frontiers. Asian Journal of Pharmaceutical Research. 2026; 16(3):262-8. doi: 10.52711/2231-5691.2026.00039
Cite(Electronic):
Yash Manoj Jadhav, Rupali Jalindar Ghule, Priyal Nilesh Jadhav, Samadhan Gajendra Jaybhave, Mukund M. Pache, Avinash B. Darekar. Advances in Novel Drug Delivery Systems: Materials, Mechanisms and Therapeutic Frontiers. Asian Journal of Pharmaceutical Research. 2026; 16(3):262-8. doi: 10.52711/2231-5691.2026.00039 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-3-7
REFERENCES:
1. Luhar M, Viradiya R, Panjabi S, et al. Nanotechnology in Ocular Drug Delivery: The Potential of Polymeric Micelles as a Drug Delivery Vehicle. Journal of Ocular Pharmacology and therapeutics : The official Journal of The Association for Ocular Pharmacology and Therapeutics. 2025; 41(2): 54–64; doi: 10.1089/jop.2024.0060.
2. Chatterjee P, Dhibar S. Nanomaterial marvels: Pioneering applications and cutting-edge advancements in drug delivery. Nano and Medical Materials 2023; 220; doi: 10.59400/nmm.v3i1.220.
3. Roszkowski S, Durczynska Z. Advantages and limitations of nanostructures for biomedical applications. Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University 2024;34(3):447–456; doi: 10.17219/acem/186846.
4. Prakash S. Nano-based drug delivery system for therapeutics: a comprehensive review. Biomedical Physics andamp; Engineering Express. 2023; 9(5): 052002; doi: 10.1088/2057-1976/acedb2.
5. Pacardo DB, Ligler FS, Gu Z. Programmable nanomedicine: synergistic and sequential drug delivery systems. Nanoscale 2015; 7(8): 3381–3391; doi: 10.1039/c4nr07677j.
6. Ullah M, Hasan MW, Inam M, et al. Engineered metal nanoparticles for precision drug delivery: Pioneering the future of medicine: Mini review. Journal of the Chinese Chemical Society. 2024; 71(11): 1358–1367; doi: 10.1002/jccs.202400179.
7. Khatoon N, Zhou CH, Chu MQ. Nanoclay-based drug delivery systems and their therapeutic potentials. Journal of Materials Chemistry B. 2020; 8(33): 7335–7351; doi: 10.1039/d0tb01031f.
8. Chen J, Wang Y, Luo L, et al. Dual tumor-targeted poly(lactic-co-glycolic acid)-polyethylene glycol-folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery. International Journal of Nanomedicine. 2017; 12(2): 5745–5760; doi: 10.2147/ijn.s136488.
9. Amin MK, Boateng JS. Enhancing Stability and Mucoadhesive Properties of Chitosan Nanoparticles by Surface Modification with Sodium Alginate and Polyethylene Glycol for Potential Oral Mucosa Vaccine Delivery. Marine Drugs. 2022; 20(3): 156; doi: 10.3390/md20030156.
10. Lacroce E, Rossi F. Polymer-based thermoresponsive hydrogels for controlled drug delivery. Expert Opinion on Drug Delivery. 2022; 19(10): 1203–1215; doi: 10.1080/17425247.2022.2078806.
11. Viegas C, Patrício AB, Prata JM, et al. Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review. Pharmaceutics 2023; 15(6): 1593; doi: 10.3390/pharmaceutics15061593.
12. Duan Y, Patel C, Siva Kumar N, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Advances. 2020; 10(45): 26777–26791; doi: 10.1039/d0ra03491f.
13. Tenchov R, Curtze AE, Bird R, et al. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021; 15(11): 16982–17015; doi: 10.1021/acsnano.1c04996.
14. Pache MM, Pangavhane RR, Nikam SV, et al. CRISPR-Cas9 in Pharmaceutical Research: Applications, Challenges, Ethical Considerations and Future Directions. Asian Journal of Pharmacy and Technology. 2025.
15. Girija AR, Balasubramanian S. Theragnostic potentials of core/shell mesoporous silica nanostructures. Nanotheranostics. 2019; 3(1): 1–40; doi: 10.7150/ntno.27877.
16. Patil JH, Patil PO, Patel JK, et al. A Comprehensive Review on Metal–Organic Frameworks for Stimuli-responsive-based Drug Delivery: Recent Advances and Future Trends. Nano Biomedicine and Engineering. 2024; 16(3): 285–308; doi: 10.26599/nbe.2024.9290078.
17. Hao X, Zhang W, Feng Y, et al. Red-blood-cell-mimetic gene delivery systems for long circulation and high transfection efficiency in ECs. Journal of Materials Chemistry B 2018; 6(37): 5975–5985; doi: 10.1039/c8tb01789a.
18. Kang W, Xu Z, Lu H, et al. Advances in biomimetic nanomaterial delivery systems: harnessing nature’s inspiration for targeted drug delivery. Journal of Materials Chemistry B 2024; 12(29): 7001–7019; doi: 10.1039/d4tb00565a.
19. Rao Khadam VK, Kumari P, Singh RP, et al. An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. Asian Journal of Pharmaceutical Research and Development. 2024; 12(1): 55–64; doi: 10.22270/ajprd.v12i1.1349.
20. Caro C, Avasthi A, Pernia Leal M, et al. Passive targeting of high-grade gliomas via the EPR effect: a closed path for metallic nanoparticles? Biomaterials Science 2021;9(23):7984–7995; doi: 10.1039/d1bm01398j.
21. Yan Y, Chen B, Zhang Q, et al. Sequential Modulations of Tumor Vasculature and Stromal Barriers Augment the Active Targeting Efficacy of Antibody-Modified Nanophotosensitizer in Desmoplastic Ovarian Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2020; 8(3): 2002253; doi: 10.1002/advs.202002253.
22. Hua Q, Chu M, Ren J, et al. Polymeric Drug Delivery System with Actively Targeted Cell Penetration and Nuclear Targeting for Cancer Therapy. ACS Applied Bio Materials. 2019; 2(4): 1724–1731; doi: 10.1021/acsabm.9b00097.
23. Bajracharya R, Song JG, Patil BR, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Delivery. 2022; 29(1): 1959–1970; doi: 10.1080/10717544.2022.2089296.
24. Alqaraghuli HGJ, Rafipour R, Kashanian S. A Review on Targeting Nanoparticles for Breast Cancer. Current Pharmaceutical Biotechnology. 2019; 20(13): 1087–1107; doi: 10.2174/1389201020666190731130001.
25. Pache MM, Pangavhane RR. Immunotherapy in Autoimmune Diseases: Current Advances and Future Directions. Asian Journal of Pharmaceutical Research. 2025; 15(2): 183–191; doi: 10.52711/2231-5691.2025.00030.
26. Weinstein LA, Wei B. Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes. Nanomaterials. 2025; 15(10): 739; doi: 10.3390/nano15100739.
27. Elsherbeny A, Alexander C, Grabowska AM, et al. Responsive Nanomaterial Delivery Systems for Pancreatic Cancer Management. Advanced Therapeutics. 2023; 7(3); doi: 10.1002/adtp.202300330.
28. Sheng Y, Hu J, Shi J, et al. Stimuli-responsive Carriers for Controlled Intracellular Drug Release. Current Medicinal Chemistry. 2019; 26(13): 2377–2388; doi: 10.2174/0929867324666170830102409.
29. Lu L, Armstrong EA, Yager JY, et al. Sustained Release of Dexamethasone from Sulfobutyl Ether β‐cyclodextrin Modified Self‐Assembling Peptide Nanoscaffolds in a Perinatal Rat Model of Hypoxia–Ischemia. Adv Healthcare Materials. 2019; 8(11): 1900083; doi: 10.1002/adhm.201900083.
30. Han X, Matsuda N, Ishibashi Y, et al. An In Vitro Assessment Method for Chemotherapy-Induced Peripheral Neurotoxicity Caused by Anti-Cancer Drugs Based on Electrical Measurement of Impedance Value and Spontaneous Activity. Pharmaceutics. 2023; 15(12): 2788; doi: 10.3390/pharmaceutics15122788.
31. Jain M, Singh P. Rare-Earth-Activated Phosphors for Drug Delivery. In: Rare-Earth-Activated Phosphors Elsevier; 2022; pp. 339–362; doi: 10.1016/B978-0-323-89856-0.00015-8.
32. Bale S, Khurana A, Godugu C, et al. Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems. Critical ReviewsTM in Therapeutic Drug Carrier Systems. 2016; 33(4): 309–361; doi: 10.1615/critrevtherdrugcarriersyst.2016015798.
33. Huang Y, Cai T, Cai Y, et al. Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer. Oncology Letters 2016;12(1):11–15; doi: 10.3892/ol.2016.4596.
34. Masane N, Katekar V, Akhand V, et al. Nanoparticles based drug delivery system for cancer therapy. GSC Advanced Research and Reviews. 2025; 22(1): 223–237; doi: 10.30574/gscarr.2025.22.1.0014.
35. Ghule RJ, Jadhav PN, Sanap YN, Pache MM, DarekarAB. Tumour-derived extracellular vesicles in chemotherapy resistance: Molecularpathways, clinical implications and therapeutic opportunities. Asian J ResPharm Sci. 2025; 15(4): 371–380. doi:10.52711/2231-5659.2025.00055
36. Choi H, Choi K, Choi C, et al. Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges. Pharmaceutics. 2022; 14(3): 672; doi: 10.3390/pharmaceutics14030672.
37. Joshi BS, Zuhorn IS. Heparan sulfate proteoglycan-mediated dynamin-dependent transport of neural stem cell exosomes in an in vitro blood-brain barrier model. European Journal of Neuroscience. 2020; 53(3): 706–719; doi: 10.1111/ejn.14974.
38. Pache M, Kedar H, Kond S, et al. Pharmacological Management of Neurodegenerative Disorders: Current and Future Approaches. Int J Sci R Tech. 2025; 2(3): 405–520; doi: 10.5281/ZENODO.15074000.
39. Dobrovolskaia MA. Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory. Frontiers in Immunology. 2022; 13(3). doi: 10.3389/fimmu.2022.984252.
40. Pache M, Nikam S. Antibiotic Resistance: Current Challenges and Future Directions. Int J of Pharm Sci. 2025; 3(1): 1600–1622; doi: 10.5281/ZENODO.14690670.
41. Jafari M, (Sarkari) BS, Zomorodian K, et al. Nanotechnology Approaches for Delivery and Targeting of Amphotericin B in Fungal and Parasitic Diseases. Nanomedicine. 2021; 16(10): 857–877; doi: 10.2217/nnm-2020-0482.
42. Domingo-Lopez DA, Lattanzi G, H J Schreiber L, et al. Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. Advanced Drug Delivery Reviews. 2022; 185: 114280; doi: 10.1016/j.addr.2022.114280.
43. Pangavhane R, Pache M. Phytochemicals in The Management of Diabetes Mellitus: A Comprehensive Review. Int J Sci R Tech. 2025; 2(4): 6–14; doi: 10.5281/zenodo.15122232.
44. Sun R, Yu L, Yu Z, et al. Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine. Journal of Nanobiotechnology. 2022; 20(1) doi: 10.1186/s12951-022-01389-7.
45. Ullah A, Khan M, Zhang Y, et al. Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment. International Journal of Nanomedicine. 2025; 20: 25–52; doi: 10.2147/ijn.s429279.
46. Klyachko NL, Gololobova OA, Arzt CJ, et al. Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations. Pharmaceutics. 2020; 12(12): 1171; doi: 10.3390/pharmaceutics12121171.
47. El-Tanani M, Rabbani SA, Babiker R, et al. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Letters. 2024; 591: 216894; doi: 10.1016/j.canlet.2024.216894.
48. Singh A, Kukreti R, Saso L, et al. Mechanistic Insight into Oxidative Stress-Triggered Signaling Pathways and Type 2 Diabetes. Molecules. 2022; 27(3): 950; doi: 10.3390/molecules27030950.
49. Pache MM, Pangavhane RR, Jagtap MN, et al. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian J Res Pharm Sci. 2025; 15(1): 61–67; doi: 10.52711/2231-5659.2025.00009.
50. Delgado-Pujol EJ, Martínez G, Casado-Jurado D, et al. Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems. Pharmaceutics. 2025; 17(2): 215; doi: 10.3390/pharmaceutics17020215.
51. Pache M, Bachhav G, Bhamare A, et al. Mapping Drug Responses Through Multi-Omics: A New Era of Bioinformatics in Precision Medicine. Int J Sci R Tech. 2025; 2(8): 319–335; doi: 10.5281/ZENODO.16914606.